November 30, 2016 - By kentuckypostne · 0 Comments
The stock of Concert Pharmaceuticals Incorporated (NASDAQ:CNCE) registered an increase of 14.87% in short interest. CNCE’s total short interest was 599,600 shares in November as published by FINRA. Its up 14.87% from 522,000 shares, reported previously. With 89,100 shares average volume, it will take short sellers 7 days to cover their CNCE’s short positions. The short interest to Concert Pharmaceuticals Incorporated’s float is 4.15%. The stock increased 0.43% or $0.04 on November 29, hitting $9.35. Concert Pharmaceuticals Inc (NASDAQ:CNCE) has declined 33.64% since April 27, 2016 and is downtrending. It has underperformed by 38.87% the S&P500.
Concert Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company has a market cap of $202.61 million. The Firm is engaged in the discovery and development of small molecule drugs. It currently has negative earnings. The Firm operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment.
Insitutional Activity: The institutional sentiment decreased to 1 in 2016 Q2. Its down 0.39, from 1.39 in 2016Q1. The ratio dived, as 8 funds sold all Concert Pharmaceuticals Inc shares owned while 25 reduced positions. 11 funds bought stakes while 35 increased positions. They now own 13.09 million shares or 2.13% less from 13.37 million shares in 2016Q1.
Moreover, Putnam Invests Ltd Llc has 0% invested in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 163,131 shares. Awm Inv Inc accumulated 100,000 shares or 0.24% of the stock. Bvf Il owns 2.76 million shares or 6.59% of their US portfolio. Shinko Asset Ltd holds 0% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 55,934 shares. Plante Moran Fincl Advsrs Limited Liability Company holds 0.01% or 1,500 shares in its portfolio. Bogle Investment Mngmt L P De holds 0.01% or 11,909 shares in its portfolio. Barclays Public Ltd Co holds 365 shares or 0% of its portfolio. Natl Bank Of Ny Mellon holds 125,269 shares or 0% of its portfolio. Senzar Asset Mgmt Limited Liability Corporation holds 800,788 shares or 0% of its portfolio. Baker Bros Advisors Limited Partnership has 0.06% invested in the company for 470,058 shares. Blackrock Japan Company Limited holds 0% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 998 shares. Goldman Sachs Grp holds 0% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE) for 12,434 shares. The New York-based Teachers Advsr Inc has invested 0% in Concert Pharmaceuticals Inc (NASDAQ:CNCE). Credit Suisse Ag reported 34,894 shares or 0% of all its holdings. Proshare Lc has invested 0% of its portfolio in Concert Pharmaceuticals Inc (NASDAQ:CNCE).
Insider Transactions: Since November 14, 2016, the stock had 0 buys, and 1 insider sale for $217,027 net activity. HUTT PETER BARTON had sold 22,123 shares worth $217,027 on Monday, November 14.
Out of 7 analysts covering Concert Pharmaceuticals (NASDAQ:CNCE), 6 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. $32.0 is the highest target while $21 is the lowest. The $27.80 average target is 197.33% above today’s ($9.35) stock price. Concert Pharmaceuticals has been the topic of 9 analyst reports since August 12, 2015 according to StockzIntelligence Inc. Stifel Nicolaus initiated the shares of CNCE in a report on Friday, July 1 with “Buy” rating. The rating was initiated by Brean Capital with “Buy” on Wednesday, August 12. The firm earned “Neutral” rating on Monday, November 9 by UBS. The rating was maintained by Roth Capital with “Buy” on Tuesday, September 22. The company was maintained on Wednesday, March 9 by JMP Securities. The stock of Concert Pharmaceuticals Inc (NASDAQ:CNCE) has “Buy” rating given on Wednesday, September 9 by Aegis Capital. The rating was maintained by TH Capital on Tuesday, September 22 with “Buy”.
Concert Pharmaceuticals, Inc., incorporated on April 12, 2006, is a clinical-stage biopharmaceutical company. The Firm is engaged in the discovery and development of small molecule drugs. The Firm operates through the development of pharmaceutical products on its own behalf or in collaboration with others segment. The Firm has clinical candidates under development, including AVP-786, CTP-656, CTP-730 and JZP-386. The Company’s deuterated chemical entity platform (DCE Platform) enables it to identify compounds for deuteration and to design, evaluate, develop and manufacture deuterated compounds. The Firm is utilizing its DCE Platform to discover and develop product candidates for a range of indications.
More notable recent Concert Pharmaceuticals Inc (NASDAQ:CNCE) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on February 14, 2014, also Businesswire.com with their article: “Concert Pharmaceuticals Expands Management Team” published on September 06, 2016, Businesswire.com published: “Concert Pharmaceuticals Reports Second Quarter 2016 Financial Results and …” on August 09, 2016. More interesting news about Concert Pharmaceuticals Inc (NASDAQ:CNCE) were released by: Seekingalpha.com and their article: “Concert Pharmaceuticals: At 52 Week Lows With Upcoming Catalysts” published on October 18, 2016 as well as Globenewswire.com‘s news article titled: “Concert Pharmaceuticals, Inc. (Nasdaq: CNCE) to Ring The Nasdaq Stock Market …” with publication date: October 24, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.